CN102492040A - Method for purifying anti-HER2 or/and anti-HER3 antibody proteins - Google Patents
Method for purifying anti-HER2 or/and anti-HER3 antibody proteins Download PDFInfo
- Publication number
- CN102492040A CN102492040A CN2011104528376A CN201110452837A CN102492040A CN 102492040 A CN102492040 A CN 102492040A CN 2011104528376 A CN2011104528376 A CN 2011104528376A CN 201110452837 A CN201110452837 A CN 201110452837A CN 102492040 A CN102492040 A CN 102492040A
- Authority
- CN
- China
- Prior art keywords
- virus
- purification process
- process according
- value
- filtration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention belongs to the biochemistry technical field, concretely relates to a method for purifying anti-HER2 or/and anti-HER3 antibody proteins. The method of the invention comprises the following the steps: clarifying a broth, carrying out affinity chromatography, carrying out inactivation on virus by acidic pH value, carrying out cation exchange chromatography, carrying out anion exchange chromatography; and filtering virus; wherein, the step of virus inactivation by acidic pH value and the step of virus filtration can be inserted at any position of the step after the affinity chromatography. The method of the invention comprises the following advantages that: 1) the chromatography step can be reduced to three steps, thereby the production efficiency can be enhanced and the production cost can be minimized. 2) the step of virus filtration is added, thereby the security can be raised.
Description
Technical field
The invention belongs to technological field of biochemistry, be specifically related to a kind of anti-HER2 or/and the purification process of anti-HER3 antibody protein.
Background technology
Along with the development of biological medicine technology, increasing mammalian cell is used for the manufacture of therapeutic recombinant protein, such as: monoclonal antibody, cytokine, hormone, growth factor, other also has some enzyme, thrombin etc.The treatment field that relates to also more and more widely comprises internal secretion, cardiovascular and cerebrovascular, surgery, hemopathy, antitumor or the like.
In the production process of therapeutic recombinant protein; People often can be variant according to the size between every kind of albumen, shape, electric charge, hydrophobicity, solubleness and BA; Utilize these differences to go out target protein through adopting IX (IEX), gel-filtration (GF), hydrophobic (HIC), anti-phase (RPC), affine several different methods combination and separation such as (AC); Such as monoclonal antibody, after the generation of cell fermentation supernatant, need purge process through a plurality of steps; Just can reach enough purity, be used for the injection of human body.The composition of fermented feed liquid is very complicated, and target protein only accounts for wherein very little part, and the protein purification step is many more, and the recovery of target protein is just low more.As the monoclonal antibody drug
of the anti-HER2 that sells on the market is that its purifying process flow process is by the production of U.S. Genentech company: cell conditioned medium results, albumin A chromatography, low pH inactivation of virus, cation-exchange chromatography, anion-exchange chromatography, hydrophobic chromatography.The deficiency of this technology has: 1) chromatographic step is many, and four chromatography processes are arranged.2) virus-free filtration step.Has the potential virus risk.
Summary of the invention
Technical problem to be solved by this invention is or/and the problem of anti-HER3 purification process to existing anti-HER2; A kind of anti-HER2 is provided or/and the purification process of anti-HER3 so that can simplify purification step, improves the recovery of target protein; And can remove virus, reduce the potential virus risk.
For this reason, the invention discloses a kind of anti-HER2 or/and the purification process of anti-HER3 antibody protein comprises the following steps:
Clarified broth;
Affinity chromatography;
The acid ph value inactivation of virus;
Cation-exchange chromatography;
Anion-exchange chromatography;
Virus filtration; Wherein said acid ph value inactivation of virus step and virus filtration step can arbitrarily be interted arbitrary step location after the affinity chromatography step.
In certain embodiments, said anti-HER2 is or/and anti-HER3 antibody protein is an Anti-HER 2 albumen.
In certain embodiments, the clarification mode of said fermented feed liquid is one of in centrifugal, Depth Filtration or the terminal micro-filtration or any combination, can according to the state of fermented feed liquid with handle volume, can adopt different processing modes or combination.Wherein preferred Depth Filtration most preferably is and adopts the two-stage Depth Filtration, and filter membrane is D0HC of Millipore company and A1HC filter membrane.Depth Filtration is newer a kind of filter type; It has adopted loose many empty cellulose skeleton structures, and has filled the zeyssatite composition, the surface apertures funnel of sample introduction end; These structures have been abandoned traditional micro-filtration surface and have been held back structure and be prone to cause obstruction, shortcoming that filtration efficiency is low; Possessed the unexistent advantage of holding back the small volume cell debris of whizzer again, relied on diatomaceous adsorption simultaneously, can hold back up to 50% DNA and 15% HCP.
In certain embodiments, said anti-HER2 is or/and label protein that anti-HER 3 antibody proteins have or label polypeptide (Tag).Commonly used have glutathione-S-transferase (GST-Tag), six polyhistidyl peptides (His-Tag), Arg-tag, a-protein (protein A), FLAG-Tag and a Strep-tag etc.Through the form of singularity albumen or polypeptide and target protein formation fusion rotein, utilize the special property of described label protein or label polypeptide to separate and purifying after the expression to target protein.Combine with Ni-Chelating Sepharose post specificity like His-Tag; Arg-tag can be attached on the Zeo-karb SP-Sephadex; GST-Tag combines with the chromatography media of crosslinked gsh; Described label protein or label polypeptide can be removed fusion sequence with the locus specificity protease digestion behind purifying, like available zymoplasm, enteropeptidase and Xa factor etc., to obtain target protein.
In certain embodiments, said affinity chromatography is the albumin A affinity chromatography, utilizes the absorption of albumin A antagonist Fc fragment high specific, can reach the purity more than the antibody recovery and 99% more than 95%.
The condition of said albumin A affinity chromatography is flow velocity: 300 ± 100cm/h; Post is high: 20 ± 2cm; Level pad: 25mM Tris-HCl+75mM NaCl, pH 7.2 ± 0.2; Elutriant: the 100mM sodium-acetate, pH 3.6 ± 0.1.
Said acid ph value inactivation of virus is for adjusting the pH value to subacidity (pH value about 3.7).Under this pH value, the outer film destroy of film virus loses infectivity.But,, then do not have inactivating efficacy for the Virus Type that does not have adventitia.Said acid ph value inactivation of virus step is for adding 20% acetate, adjustment pH value to 3.7 ± 0.1, room temperature placement 1-2 hour, adding 2M Tris adjustment pH value to 5.2 ± 0.2.
In certain embodiments, the condition of said cation-exchange chromatography is flow velocity: 100-180cm/h; Post is high: 20 ± 2cm; The pre-equilibration damping fluid: the 100mM acetate buffer adds 1M NaCl, and pH 5.0 ± 0.4; Level pad: the 50mM acetate buffer, pH 5.2 ± 0.2; Elutriant: the 260mM acetate buffer, pH 6.0 ± 0.2.Sample pH value is 5.2 ± 0.2, and electricity is led and is 2.0-3.0mS/cm.
The principle of cation-exchange chromatography is an electronegative group on positively charged zone of molecular surface and the chromatographic stuffing, and the electrostatic attraction through the charges of different polarity combines.The charged degree of different molecular surfaces has determined its static to combine intensity of force, thereby in the chromatography process, obtains separating.The antibody molecule surface often has the zone with a large amount of positive charges, and it combines the ability of filler to be higher than general impurity, for example most of host protein, intracellular toxin, DNA, the Protein A that comes off etc.In addition, cation-exchange chromatography can also be removed antibody polymerization thing, impurity such as isomer effectively.
Anion-exchange chromatography often adopts stream to wear pattern, and promptly protein stream is crossed chromatography column and impurity is bonded on the chromatography column.Through this step of anion-exchange chromatography, albumen further is removed impurity such as remaining DNA, potential virus, host protein, intracellular toxin, makes through this step purified proteins solution to conform to quality requirements fully.
In certain embodiments, the condition of said anion-exchange chromatography is flow velocity: 180-360cm/h; Post is high: 20 ± 2cm; The pre-equilibration damping fluid: 50mM Tris-HCl adds 1M NaCl, and pH 8.0 ± 0.4; Level pad: 50mM Tris-HCl adds 10mM NaCl, and pH 8.0 ± 0.2; Sample: the anion-exchange chromatography eluted protein, adjustment pH to 8.0 ± 0.2, electricity is led 3.0-5.0mS/cm.
In certain embodiments, said virus filtration is the virus filtration in a step 20nm aperture, guarantees that any virion that possibly exist all is removed.Because the diameter of virion is often all greater than 20nm, virus can reliablely and stablely be removed (clearances of＞4 log values) through this filtration step.With sample behind the anion-exchange chromatography, filter the virus filtration film with pressurized air (2.0-2.2Bar).
The method of the invention has following advantage: 1) chromatographic step was reduced to for three steps, had improved production efficiency, had reduced production cost.2) increase the virus filtration process, improved security.
Embodiment
Below in conjunction with specific embodiment, further set forth the present invention.These embodiment only be used to the present invention is described and be not used in the restriction scope of the present invention.The experimental technique of unreceipted actual conditions in the following example is usually according to the normal condition or the condition of advising according to manufacturer.Only if definition separately, the same meaning that employed all specialties and scientific words and one skilled in the art are familiar with in the literary composition.In addition, any with the institute similar content of putting down in writing or the equalization method and material all can be applicable in the inventive method.The usefulness that preferable implementation method described in the literary composition and material only present a demonstration.
1. the results of fermented liquid supernatant
Adopt the method for two-stage Depth Filtration.
Fermented liquid: the fermented liquid that contains anti-HER 2 monoclonal antibody of the expressed generation of cell strain of good and biological medicine company.
Filter membrane: D0HC of Millipore company and A1HC filter membrane.(also can adopt the Depth Filtration filter membrane of other producers)
Process: use is preceding with gas in the purified water emptying filter, and fully soaks into filter; Turbidity is surveyed in sampling before the filtering fermentation liquor, utilizes peristaltic pump to make fermented liquid pass through filter at the flow velocity of 100-300LMH; The intact back of filtering fermentation liquor residual liquid in film bag bubbling air emptying film bag, the feed liquid after the filtration mixes back sampling and measuring turbidity.
5 batches clarification result:
2. albumin A chromatography
Filler (resin): the affine filler of Protein A (not limiting kind)
Flow velocity: 300 ± 100cm/h
Post is high: 20 ± 2cm
Level pad: 25mM Tris-HCl+75mM NaCl, pH 7.2 ± 0.2
Elutriant: the 100mM sodium-acetate, pH 3.6 ± 0.1
Sample:, directly go up appearance through clarifying excavation liquid.Applied sample amount is 0-50g albumen/L filler.
Chromatographic step:, begin to go up appearance then earlier with 3 column volumes of level pad balance.After the last appearance, with 5 column volumes of level pad flushing.5 column volumes of wash-out are collected elution peak subsequently.Chromatography column after the use need clean and preserve.
3. low pH value inactivation of virus
PH adjusts damping fluid one: 2M Tris
Two: 20% (V/V) acetate of pH adjustment damping fluid
Step: add 20% acetate and place 1-2 hour-adjustment pH value to 5.0, use the Depth Filtration filter membrane (A1HC) of Millipore to filter then to pH 3.7 ± 0.1-room temperature.
4. cation-exchange chromatography
Filler (resin): cationic exchange filler (Fractogel COO (M))
Flow velocity: 100-180cm/h
Post is high: 20 ± 2cm
The pre-equilibration damping fluid: the 100mM acetate buffer adds 1M NaCl, and pH 5.0 ± 0.4
Level pad: the 50mM acetate buffer, pH 5.2 ± 0.2
Elutriant: the 260mM acetate buffer, pH 6.0 ± 0.2
Sample: albumen behind the inactivation of virus, adjustment pH to 5.2 ± 0.2, electricity is led 2.0-3.0mS/cm, and applied sample amount is 0-45g albumen/L filler.
Chromatographic step:, use 2 column volumes of level pad balance subsequently earlier with 2 column volumes of pre-equilibration damping fluid balance.Adjusting to appearance on target pH and the electric sample of leading.After last appearance finishes, with 2 column volumes of level pad balance.Begin wash-out then, 10 column volumes of linear gradient, the 0-100% elutriant is collected elution peak, and the chromatography column after the use cleans with 0.5M NaOH+1MNaCl, preserves with 0.1MNaOH
5. anion-exchange chromatography
Filler (resin): anion exchange filler (Capto Q)
Flow velocity: 180-360cm/h
Post is high: 20 ± 2cm
The pre-equilibration damping fluid: 50mM Tris-HCl adds 1M NaCl, and pH 8.0 ± 0.4
Level pad: 50mM Tris-HCl adds 10mM NaCl, and pH 8.0 ± 0.2
Sample: the cation-exchange chromatography eluted protein, adjustment pH to 8.0 ± 0.2, electricity is led 3.0-5.0mS/cm, and applied sample amount is 0-500g albumen/L filler.
Chromatographic step: earlier with 2 column volumes of pre-equilibration damping fluid balance, 2 column volumes of balance then.With appearance on the sample solution of adjusting to target pH and electric conductivity value, when ultraviolet absorption value arrives 0.1AU (280nm wavelength), begin to collect stream and wear the peak.Behind the end of the sample, use 2 column volumes of level pad balance again.The stream of collecting is worn the peak with 20% acetate adjustment pH to 5.0.Chromatography column after the use needs to clean with 0.5MNaOH+1MNaCl, preserves with 0.1M NaOH.
6. virus filtration
Filter membrane: 20nm virus filtration film (any manufacturer, we select Millipore
Pro for use)
Working pressure: 2.0-2.2Bar
Operating process: with sample behind the anion-exchange chromatography, filter the virus filtration film with pressurized air (2.0-2.2Bar).
7. the recovery
Calculate 3 batches of fermented liquids through before and after the above-mentioned purification step, the proteic recovery of Anti-HER 2, the result is following:
| Lot number | 1 | 2 | 3 |
| The recovery | 101.7％ | 96.9％ | 98.0％ |
Discuss:
The present invention is a kind of downstream purification method that is directed to the monoclonal antibody of anti-HER2 and HER3.This method is compared with Herceptin (anti-HER2 monoclonal antibody marketed drug) the purifying flow process of Genentech company; 1) through improving chromatography condition; It was three steps that four step chromatographic step of original Genentech company are simplified, and kept quality product to meet the requirement of rules simultaneously.(it is low that the hydrophobic chromatography step often has the albumen carrying capacity owing to the hydrophobic chromatography step in the purifying process that has removed original Genentech; The high shortcoming of concentration of salt solution that needs; Thereby production cost is higher relatively), thus production efficiency improved, reduced production cost.2) compare with the technology of Genentech, increased the virus filtration step of 20nm specification in our purifying process, improved security of products.
Scope of the present invention does not receive the restriction of said specific embodiments, and said embodiment also comprises the method and the component of functional equivalent only as the single example of illustrating all respects of the present invention in the scope of the invention.In fact, except content as herein described, those skilled in the art can easily grasp multiple improvement of the present invention with reference to the description and the accompanying drawing of preceding text.Said improvement also falls within the scope of appended claims.Every piece of reference that preceding text are mentioned is listed this paper in as a reference all in full.
Claims (9)
- An anti-HER2 or/and the purification process of anti-HER3 antibody protein comprise the following steps:A) clarified broth;B) affinity chromatography;C) acid ph value inactivation of virus;D) cation-exchange chromatography;E) anion-exchange chromatography;F) virus filtration;Wherein said acid ph value inactivation of virus step and virus filtration step can arbitrarily be interted arbitrary step location after the affinity chromatography step.
- 2. purification process according to claim 1 is characterized in that said anti-HER2 or/and anti-HER3 antibody protein is an Anti-HER 2 albumen.
- 3. purification process according to claim 1 is characterized in that said clarification mode is one of in centrifugal, Depth Filtration or the terminal micro-filtration or two or more combination arbitrarily.
- 4. purification process according to claim 3 is characterized in that said Depth Filtration is the two-stage Depth Filtration, and filter membrane is D0HC of Millipore company and A1HC filter membrane.
- 5. purification process according to claim 1 is characterized in that said affinity chromatography is the albumin A affinity chromatography.
- 6. purification process according to claim 1, the condition that it is characterized in that said albumin A affinity chromatography is flow velocity: 300 ± 100cm/h; Post is high: 20 ± 2cm; Level pad: 25mM Tris-HCl+75mM NaCl, pH 7.2 ± 0.2; Elutriant: the 100mM sodium-acetate, pH 3.6 ± 0.1.
- 7. purification process according to claim 1 is characterized in that said acid ph value inactivation of virus step is for adding 20% acetate, adjustment pH value to 3.7 ± 0.1, room temperature placement 1-2 hour, adding 2M Tris adjustment pH value to 5.2 ± 0.2.
- 8. purification process according to claim 1, the condition that it is characterized in that said cation-exchange chromatography is flow velocity: 100-180cm/h; Post is high: 20 ± 2cm; The pre-equilibration damping fluid: the 100mM acetate buffer adds 1M NaCl, and pH 5.0 ± 0.4; Level pad: the 50mM acetate buffer, pH 5.2 ± 0.2; Elutriant: the 260mM acetate buffer, pH 6.0 ± 0.2; Sample pH value is 5.2 ± 0.2, and electricity is led 2.0-3.0mS/cm.
- 9. purification process according to claim 1, the condition that it is characterized in that said anion-exchange chromatography is flow velocity: 180-360cm/h; Post is high: 20 ± 2cm; The pre-equilibration damping fluid: 50mM Tris-HCl adds 1M NaCl, and pH 8.0 ± 0.4; Level pad: 50mM Tris-HCl adds 10mM NaCl, and pH 8.0 ± 0.2; Sample: the anion-exchange chromatography eluted protein, adjustment pH to 8.0 ± 0.2, electricity is led 3.0-5.0mS/cm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110452837.6A CN102492040B (en) | 2011-12-29 | 2011-12-29 | Method for purifying anti-HER2 or/and anti-HER3 antibody proteins |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201110452837.6A CN102492040B (en) | 2011-12-29 | 2011-12-29 | Method for purifying anti-HER2 or/and anti-HER3 antibody proteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102492040A true CN102492040A (en) | 2012-06-13 |
| CN102492040B CN102492040B (en) | 2014-06-25 |
Family
ID=46183907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201110452837.6A Active CN102492040B (en) | 2011-12-29 | 2011-12-29 | Method for purifying anti-HER2 or/and anti-HER3 antibody proteins |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102492040B (en) |
Cited By (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104411820A (en) * | 2012-06-29 | 2015-03-11 | Emd密理博公司 | Methods for inactivating viruses during a protein purification process |
| CN105017418A (en) * | 2014-03-27 | 2015-11-04 | 上海药明康德新药开发有限公司 | Monoclonal antibody purification process |
| CN105121469A (en) * | 2013-04-04 | 2015-12-02 | 麦布西恩斯公司 | A method for increasing pyro-glutamic acid formation of a protein |
| CN106146660A (en) * | 2015-04-16 | 2016-11-23 | 湖北生物医药产业技术研究院有限公司 | The method of isolated and purified monoclonal antibody |
| CN106380519A (en) * | 2016-10-17 | 2017-02-08 | 深圳万乐药业有限公司 | Purification method of monoclonal antibodies |
| CN106496302A (en) * | 2015-09-08 | 2017-03-15 | 三生国健药业（上海）股份有限公司 | One kind uses cation exchange chromatography method of protein |
| CN106565844A (en) * | 2016-11-08 | 2017-04-19 | 深圳万乐药业有限公司 | Method for deep filtration of monoclonal antibody cell culture liquid |
| CN106867985A (en) * | 2015-12-11 | 2017-06-20 | 上海天士力药业有限公司 | A kind of purifying of recombinant human urokinase zymogen and removal viral methods |
| CN109336969A (en) * | 2018-11-09 | 2019-02-15 | 杭州奕安济世生物药业有限公司 | A kind of purification process of antibody |
| CN109336967A (en) * | 2018-11-09 | 2019-02-15 | 杭州奕安济世生物药业有限公司 | Antibody purification process based on mixed fillers |
| CN109929038A (en) * | 2017-12-15 | 2019-06-25 | 山东博安生物技术有限公司 | The purification process of VEGF capturing agent fusion protein |
| CN110016080A (en) * | 2019-01-15 | 2019-07-16 | 济宁学院 | A kind of purifying process of the full Humanized monoclonal antibodies of anti-EGFR |
| CN110194784A (en) * | 2019-05-07 | 2019-09-03 | 上海药明生物技术有限公司 | With the method for diatomite clarified cell fermentation liquid |
| CN110272491A (en) * | 2018-03-13 | 2019-09-24 | 江苏恒瑞医药股份有限公司 | A kind of purifying process of anti-PD-1 antibody |
| CN111269316A (en) * | 2018-12-04 | 2020-06-12 | 正大天晴药业集团南京顺欣制药有限公司 | Purification method of anti-HER 2 monoclonal antibody |
| CN111704670A (en) * | 2020-08-18 | 2020-09-25 | 迈威(上海)生物科技股份有限公司 | Disulfide bond isomer of recombinant anti-RANKL antibody IgG2 type and purification method thereof |
| CN113717281A (en) * | 2021-09-09 | 2021-11-30 | 成都蓉生药业有限责任公司 | Buffer solution for affinity chromatography for removing anti-A and anti-A hemagglutinin in intravenous injection human immunoglobulin and application thereof |
| CN114106086A (en) * | 2021-12-20 | 2022-03-01 | 苏州创胜医药集团有限公司 | Method for inactivating virus in chromatography process and application thereof |
| CN117736324A (en) * | 2022-09-22 | 2024-03-22 | 北京东方百泰生物科技股份有限公司 | Purification method of anti-Siglec-15 monoclonal antibody |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1396182A (en) * | 2002-07-31 | 2003-02-12 | 陕西超英生物医学研究开发有限公司 | Human monoclonal antibody of human endophloeodal growth factor receptor 2 protein and its preparing process |
| WO2010147686A2 (en) * | 2009-03-11 | 2010-12-23 | Wyeth Llc | Methods of purifying small modular immunopharmaceutical proteins |
| WO2011017514A1 (en) * | 2009-08-07 | 2011-02-10 | Millipore Corporation | Methods for purifying a target protein from one or more impurities in a sample |
-
2011
- 2011-12-29 CN CN201110452837.6A patent/CN102492040B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1396182A (en) * | 2002-07-31 | 2003-02-12 | 陕西超英生物医学研究开发有限公司 | Human monoclonal antibody of human endophloeodal growth factor receptor 2 protein and its preparing process |
| WO2010147686A2 (en) * | 2009-03-11 | 2010-12-23 | Wyeth Llc | Methods of purifying small modular immunopharmaceutical proteins |
| WO2011017514A1 (en) * | 2009-08-07 | 2011-02-10 | Millipore Corporation | Methods for purifying a target protein from one or more impurities in a sample |
Cited By (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107188926A (en) * | 2012-06-29 | 2017-09-22 | Emd密理博公司 | The method of inactivation of viruses in protein purification procedures |
| CN104411820A (en) * | 2012-06-29 | 2015-03-11 | Emd密理博公司 | Methods for inactivating viruses during a protein purification process |
| CN104411820B (en) * | 2012-06-29 | 2017-05-03 | Emd密理博公司 | Methods for inactivating viruses during a protein purification process |
| CN107188926B (en) * | 2012-06-29 | 2021-02-09 | Emd密理博公司 | Method for inactivating viruses during protein purification |
| CN105121469A (en) * | 2013-04-04 | 2015-12-02 | 麦布西恩斯公司 | A method for increasing pyro-glutamic acid formation of a protein |
| US10400042B2 (en) | 2013-04-04 | 2019-09-03 | Mabxience Research, S.L. | Method for increasing pyro-glutamic acid formation of a protein |
| CN105017418A (en) * | 2014-03-27 | 2015-11-04 | 上海药明康德新药开发有限公司 | Monoclonal antibody purification process |
| CN105017418B (en) * | 2014-03-27 | 2021-02-23 | 上海药明康德新药开发有限公司 | Monoclonal antibody purification process |
| CN106146660B (en) * | 2015-04-16 | 2020-01-14 | 湖北生物医药产业技术研究院有限公司 | Method for separating and purifying monoclonal antibody |
| CN106146660A (en) * | 2015-04-16 | 2016-11-23 | 湖北生物医药产业技术研究院有限公司 | The method of isolated and purified monoclonal antibody |
| CN106496302A (en) * | 2015-09-08 | 2017-03-15 | 三生国健药业（上海）股份有限公司 | One kind uses cation exchange chromatography method of protein |
| CN106496302B (en) * | 2015-09-08 | 2021-12-10 | 三生国健药业（上海）股份有限公司 | Method for purifying protein by ion exchange chromatography |
| CN106867985A (en) * | 2015-12-11 | 2017-06-20 | 上海天士力药业有限公司 | A kind of purifying of recombinant human urokinase zymogen and removal viral methods |
| CN106380519B (en) * | 2016-10-17 | 2019-11-01 | 深圳万乐药业有限公司 | A kind of purification process of monoclonal antibody |
| CN106380519A (en) * | 2016-10-17 | 2017-02-08 | 深圳万乐药业有限公司 | Purification method of monoclonal antibodies |
| CN106565844A (en) * | 2016-11-08 | 2017-04-19 | 深圳万乐药业有限公司 | Method for deep filtration of monoclonal antibody cell culture liquid |
| CN106565844B (en) * | 2016-11-08 | 2019-07-09 | 深圳万乐药业有限公司 | The method of in-depth filtration Monoclonal Antibody Cell culture solution |
| CN109929038A (en) * | 2017-12-15 | 2019-06-25 | 山东博安生物技术有限公司 | The purification process of VEGF capturing agent fusion protein |
| CN109929038B (en) * | 2017-12-15 | 2020-10-09 | 山东博安生物技术有限公司 | Purification method of VEGF (vascular endothelial growth factor) capture agent fusion protein |
| CN110272491B (en) * | 2018-03-13 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | Purification process of anti-PD-1 antibody |
| CN110272491A (en) * | 2018-03-13 | 2019-09-24 | 江苏恒瑞医药股份有限公司 | A kind of purifying process of anti-PD-1 antibody |
| CN109336967A (en) * | 2018-11-09 | 2019-02-15 | 杭州奕安济世生物药业有限公司 | Antibody purification process based on mixed fillers |
| CN109336969A (en) * | 2018-11-09 | 2019-02-15 | 杭州奕安济世生物药业有限公司 | A kind of purification process of antibody |
| CN111269316A (en) * | 2018-12-04 | 2020-06-12 | 正大天晴药业集团南京顺欣制药有限公司 | Purification method of anti-HER 2 monoclonal antibody |
| CN110016080A (en) * | 2019-01-15 | 2019-07-16 | 济宁学院 | A kind of purifying process of the full Humanized monoclonal antibodies of anti-EGFR |
| WO2020147297A1 (en) * | 2019-01-15 | 2020-07-23 | 济宁学院 | Process for purifying fully humanized anti-egfr monoclonal antibody |
| CN110194784A (en) * | 2019-05-07 | 2019-09-03 | 上海药明生物技术有限公司 | With the method for diatomite clarified cell fermentation liquid |
| CN111704670A (en) * | 2020-08-18 | 2020-09-25 | 迈威(上海)生物科技股份有限公司 | Disulfide bond isomer of recombinant anti-RANKL antibody IgG2 type and purification method thereof |
| CN113717281A (en) * | 2021-09-09 | 2021-11-30 | 成都蓉生药业有限责任公司 | Buffer solution for affinity chromatography for removing anti-A and anti-A hemagglutinin in intravenous injection human immunoglobulin and application thereof |
| CN114106086A (en) * | 2021-12-20 | 2022-03-01 | 苏州创胜医药集团有限公司 | Method for inactivating virus in chromatography process and application thereof |
| CN117736324A (en) * | 2022-09-22 | 2024-03-22 | 北京东方百泰生物科技股份有限公司 | Purification method of anti-Siglec-15 monoclonal antibody |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102492040B (en) | 2014-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102492040B (en) | Method for purifying anti-HER2 or/and anti-HER3 antibody proteins | |
| Mukherjee | Isolation and purification of industrial enzymes: advances in enzyme technology | |
| EP1827691B1 (en) | Chromatography matrix | |
| AU2015273049B2 (en) | Process for the purification of TNFR:Fc fusion protein | |
| ES2706190T3 (en) | Purification of polypeptides using two-phase tangential flow ultrafiltration | |
| JP6420756B2 (en) | Affinity chromatography matrix | |
| JP2017110017A (en) | Purification of biological molecules | |
| JP6138690B2 (en) | Method for purifying human granulocyte colony-stimulating factor from recombinant Escherichia coli | |
| Lee et al. | L-asparaginase from Erwinia carotovora: an improved recovery and purification process using affinity chromatography | |
| EP2583973A1 (en) | Method for purifying protein using amino acid | |
| WO2015041218A1 (en) | Novel antibody purification method and antibody obtained therefrom, and novel antibody purification method using cation exchanger and antibody obtained therefrom | |
| JP2022526965A (en) | Improved immunoglobulin affinity chromatography by using pre-capture aggregation | |
| CN102190722A (en) | Purifying method for recombinant human serum albumin | |
| CN101060931B (en) | Antibodies by chromatography | |
| Janson et al. | Large-scale chromatography of proteins | |
| Fan et al. | Directing membrane chromatography to manufacture α1-antitrypsin from human plasma fraction IV | |
| CN102911250A (en) | Method for purifying acidic recombinant protein medicament | |
| CN103497248A (en) | Method for separating and purifying antibody from cell culture supernatant | |
| CN109336967A (en) | Antibody purification process based on mixed fillers | |
| US6310186B1 (en) | Purification of biological preparations | |
| CN101139388A (en) | Purification renaturation method for antineoplastic medicine TAT(m)-Survivin(T34A) | |
| CN105924514A (en) | Purification method for recombinant human interleukin-12 | |
| CN103102417B (en) | Purification method of recombinant human interferon alpha 2b-CTP fusion protein | |
| EP1260518A1 (en) | Method of separating and purifying protein | |
| RU2794431C1 (en) | Improving immunoglobulin affinity chromatography by the application of pre-capture floculation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20151216 Address after: 201203, room 1043, 602 Harley Road, Zhangjiang hi tech park, Shanghai, Pudong New Area Patentee after: Genor BioPharma Co., Ltd. Patentee after: Yuxi Jiahe Biotechnology Co., Ltd. Address before: 201203, room 1043, 602 Harley Road, Zhangjiang hi tech park, Shanghai, Pudong New Area Patentee before: Genor BioPharma Co., Ltd. |